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1. Introduction 
Aortic stenosis is the most common valvular disease among the occidental population and it 
is one of the most important causes of morbidity and mortality in developed countries. It 
has an incidence of 4% among over 80 years old patients (Charlson E et al.,2006). Its 
evolution is generally slowly progressive from asymptomatic/mild aortic stenosis to the 
symptomatic/severe form when survival is dramatically reduced as well as quality of live is 
importantly impaired. (Iung B et al., 2003) 
All along natural history of this disease, patients will consult several times to specialists in 
order to adjust medical treatment and perform the indicated diagnostic tests. Occasionally 
in-hospital admittance will be unavoidable and this will necessarily arise into economic 
resources consumption, that might be assumed by actually over-the-edge and almost 
bankrupted socio-sanitary policies, at least in the most of developed countries (Varadarajan 
P, 2006; Pai RG, 2006).   
Over more tan 40 years, standard treatment for severe symptomatic aortic stenosis has been 
focused in surgical replacement of the affected valve for a mechanical prosthesis. To achieve 
this replacement, patient must mandatorily undergo several risky procedures as general 
anesthesia, median sternotomy, and aortic arch clamping and cardioplegic solution infusion 
in order to maintain cardiac arrest in diastole during the intervention, with the 
indispensable cardiopulmonary bypass pumping. (Kvidal P et al,. 2000) 
Hence, standard surgical therapy has inherent morbi-mortality risks itself that must be 
carefully evaluated, so this therapy may be not suitable for a subpopulation of candidates 
because of an excessive high-risk profile. These patients must then admit the natural history 
of this disease with a terribly poor mid-term prognosis and elevated economic expenses for 
the system. (Alexander KP et al., 2000) 
Socio-sanitary policies need to organize the diagnostic and therapeutic procedures in this 
cohort of patients in order to obtain the necessary balance that allow an adequate treatment 
with risk minimization achieving the best possible results with the lowest expenses, 
optimizing the efficiency in the management of these complex pathology. 
In this moment, several therapeutic alternatives are being studied with the aim of the risk 
reduction in the management of patients with severe aortic stenosis and surgical high-risk 
profile. These therapies do not pretend to become a substitution of the standard surgical 
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therapy but a way to reduce the burden of complication and morbidity in the subgroup of 
patients that cannot be eligible for standard surgery. (Rodés-Cabau et al., 2008) 
The present chapter is dedicated to a detailed description of the different therapeutic 
procedures that are being developed nowadays as an alternative to standard surgical 
treatment. Special surgical new techniques as low-profile mechanical prosthesis, biological 
prosthesis (both stented and stentless), homograft and Ross technique (pulmonary autograft 
in aortic position and homograft in pulmonary position) will not be commented in this 
chapter. 
2. Aortic valvuloplasty 
Aortic balloon valvuloplasty is a classical procedure firstly performed in the late fifties and 
still in use for children affected of congenital aortic stenosis with acceptable results. Its use 
in degenerative or rheumatic aortic stenosis has been abandoned in the last decades due to 
its prohibitive mid-term restenosis rates. With good results limited to the first days after 
procedure, generally approved indications for severe aortic stenosis has been displaced 
towards a bridging therapy between a critical clinical situation and a surgical replacement 
that is delayed for any cause. Other previous indications, as palliative therapy among 
patients that reject surgery, previous to non-cardiac surgery or low gradient aortic stenosis 
with severely reduced left ventricle ejection fraction are losing their sense with the 
introduction of transcatheter aortic valve implantation, but all the way this novel therapy 
requires aortic valve balloon dilatation previously to device implantation, balloon 
valvuloplasty is not only out of danger of disappear but be clearly reinforced, redirected 
towards its implication in the TAVI procedure process. (Vahanian A et al., 2004). 
3. Transcatheter aortic valve implantation: TAVI 
Andersen performed first experimental studies of transcatheter aortic valve implantation in 
the early nineties (Andersen et al., 1992). Afterwards, in year 2000, Bonhoeffer did the first 
in-human implantation of a percutaneous prosthesis in pulmonary position (Bonhoeffer P et 
al., 2000) , but it was not until 2002 when Dr. Alain Cribier performed successfully the first 
implantation in a patient affected of severe symptomatic aortic stenosis rejected for surgery, 
obtaining an excellent initial clinical result that led to a fast spreading of the technique and 
implementation of the devices (Cribier A ,. 2002). From this moment on, the development of 
valvular programs to perform catheter-based aortic stenosis treatment have been increasing 
exponentially worldwide. 
In a summarized way, the procedure consists of the implantation of a biological prosthesis 
anchored in a metallic stent over the diseased and stenotic native valve using a 
percutaneous arterial and/or venous access or a transapical access after performing a 
minithoracotomy. All of these ways to access the aortic valve have the intention to avoid the 
median sternotomy and the cardiopulmonary bypass with its implicit risks. 
First procedures were performed via catheterization of the femoral vein and accessing the 
right heart and then the aortic valve in an anterograde way through a transseptal puncture. 
Although this kind of procedure is still performed in selected patients, now the most 
frequently used technique is the retrograde method through arterial access described by 
Webb in 2005, using preferably femoral site of puncture, though subclavian or even 
ascending aorta itself can be performed to reach the aortic valve (Webb JG et al., 2006). The 
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transapical technique, described by Lichtenstein in 2006, would require surgical access with 
a minithoractomy and at this moment it is the second preferred method (Lichtenstein SV et 
al., 2006). 
TAVI is a complex technique essentially reserved for very high perisurgical risk patients. It 
is important to emphasize that, due to its complexity, the learning curve of the technique 
must be performed following a strict program that minimize the risk of complications. 
Several groups have compared initial results with those obtained after the first learning 
curve period. Webb et al reported their experience after the first 168 Edwards Sapien 
transcatheter aortic valve implantation, both transfemoral (n=113) and transapical (n=55) 
showing a decrease in 30-days mortality from 14,3% in the first 84 patients to 8,3% in the 
second half of the sample. Of course, not only the experience acquirement but the technical 
advances in the device design have contributed to this results improvement (Webb JG et al., 
2007). In the same line, Grube el al demonstrated a 73% reduction in 30-days mortality (from 
40% to 10,8%) in 102 patients who underwent 18F CoreValve system valve implantation in 
comparison with an older sample treated with the first generation 25F device (Grube E et al 
., 2005). This data suggest that, while improvements in the design of the device and the 
selection of patients keep on growing exponentially, a reduction in the learning curve 
requirements should be expected for the next generation of devices and future centre 
incorporations to this alternative technique.  
Despite this technical improvements, they will never replace the importance of the learning 
curve.  Himbert et al reported that, in relation with the initial experience of a specific centre, 
precisely the learning curve is the most important factor related to in-hospital mortality and 
mid-term survival after this kind of procedures. (Himbert D et al., 2009). 
The most important issue for the generalization of these techniques is the indispensable 
device development carried out by the medical industry. The experimental tests performed 
by the different research and development programs have the goal of optimizing results by 
minimizing complications in the access site, increasing durability, improving flexibility and 
navigability of devices, developing non-traumatic guide-wires and catheters and low-profile 
stents that allow the active fixation of the valve and its homogeneous expansion in order to 
avoid paravalvular leaks and, at the end, improve general clinical results in terms of 
morbidity and mortality.  
There are several devices commercialized, the most used are the Medtronic CoreValve® 
Transcatheter Aortic Valve Implantation System (Medtronic Inc, Minneapolis, USA) and the 
Edwards Sapien® Trancatheter Heart Valve system (Edwards Lifesciences Inc., Irvine, 
USA).  
CoreValve first implantation was reported for Grube et al in 2005 and obtained the CE mark 
in 2007. More than 10.000 devices have been already successfully implanted in more than 34 
countries, and recently a clinical trial has been approved by the Food and Drugs 
Administration to evaluate its results in the USA. At this time, this device is designed for a 
transarterial retrograde approach implantation. This device is made up of a porcine 
pericardium valve fixed to an auto-expandable nitinol stent designed to anchor both the 
outflow tract of the left ventricle and the ascending aorta. It is commercialized in two sizes: 
26mm (indicated for aortic annulus between 20 and 23mm) and 29mm (for annulus between 
23 and 27mm). It is delivered through a 18F sheath so it is intended to be used in patients 
with femoral artery diameters over 6mm.   
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The Core Valve 
The new Edwards Lifescience device, the Sapien-XT valve, can be delivered by an arterial or 
venous access site (anterograde or retrograde technique) as well as by a transapical 
approach; it has the CE mark since 2007 and has the FDA investigational device exemption 
for the PARTNER US trial.  Like the CoreValve system, more than 10.000 devices have been 
implanted all around the world with promising initial results. It is constructed with a bovine 
pericardium valve sewed to a balloon expandable chromium-cobalt stent to be anchored to 
the calcified native aortic annulus. Three sizes are commercialized: 23mm (for aortic annulus 
between 18 and 21mm), 26mm (for aortic annulus between 21 and 25mm) and the recently 
added 29mm size for annulus over 25mm. The femoral sheath is 18F for the smaller size and 
19F for the 26, and the transapical sheath is 22F for the smaller, 24F for the 26mm size and 
26F for the 29mm. No femoral system has been designed yet for the 29mm valve. 
 
 
The Edwards Sapien XT valve 
3.1 Indications 
Initially, these devices were only approved as compassionate therapy for non operable 
patients with severe symptoms (NYHA class IV dyspnea or angina), but after the initial 
results achieved, the indications of these proceedings are extending to any patient with 
symptomatic severe aortic stenosis and specific contraindication for cardiac surgery or very 
high perioperative risk profile. It is reasonable to think that, as the technique is 
consolidating, the screening of patients for TAVI should follow the general 
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recommendations for the management of patients with degenerative aortic stenosis reported 
by the scientific societies. (Vahanian A et al., 2007,2008) 
3.1.1 General indications of aortic valve replacement for aortic stenosis following the 
European Society of Cardiology clinical guidelines 
1. Patients with severe aortic stenosis and presence of any symptoms (Recommendation 
class IB). 
2. Asymptomatic patients with severe aortic stenosis and systolic dysfunction (LVEF 
<50%) not attributable to other cause (IC). 
3. Asymptomatic patients with severe aortic stenosis and exercise test that shows lowering 
of arterial systolic pressure under basal levels (IIaC). 
4. Asymptomatic patients with severe aortic stenosis and severe calcification of the valve 
and a progression of the aortic peak velocity >0,3m/s per year (IIaC). 
5. Patients with low gradient severe aortic stenosis (<40mmHg) with systolic dysfunction 
(LVEF<40%) and contractile reserve (IIaC). 
6. Asymptomatic patients with severe aortic stenosis and exercise test that shows complex 
ventricular arrhythmias (IIbC). 
7. Asymptomatic patients with severe aortic stenosis and left ventricle hypertrophy 
(>15mm) in case of no arterial hypertension (IIbC). 
8. Patients with low gradient (<40mmHg) severe aortic stenosis and systolic dysfunction 
with no contractile reserve (IIbC). 
*Severe aortic stenosis is defined as a valvular area <1cm2 (<0,6cm2/m2 of body surface 
area) or a mean gradient >50mmHg with normal flow situation. Special evaluation is 
required in case of low flow situations.  
3.1.2 Contraindication for conventional aortic valve replacement 
1. High co-morbidity: elderly patients, left ventricle dysfunction, pulmonary 
hypertension, chronic obstructive pulmonary disease, renal failure, cerebrovascular 
disease, peripheral artery disease or any other circumstances evaluated following 
EuroSCORE (European System for Cardiac Operative Risk Evaluation) or STS (Society 
of Thoracic Surgeons) scales that leads to very high-risk profiles.  
2. Excessive technical complexity: multiple re-interventions or porcelain aorta. 
3.1.3 Absence of specific contraindications for transcatheter aortic valve implantation  
In case of aortic valve replacement indication with contraindication for standard surgery or 
very high-risk patient, TAVI should be considered. If TAVI is indicated, because of slightly 
better mid-term clinical results (CITA), transarterial retrograde technique would be the 
preferred technique over the transapical approach, but always after taking into account the 
experience and/or preferences of the center. 
- General contraindications: 
1. Aortic annulus smaller than 18mm or bigger than 27mm. 
2. Bicuspid or unicuspid aortic valve. 
3. Asymmetric severe valve calcification (bulky calcification) that might lead to high risk of 
coronary ostia occlusion during implantation.  
4. Severe symptomatic coronary artery disease not suitable for percutaneous 
revascularization.  
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5. Active infective endocarditis. 
6. Hypertrophic Obstructive Myocardiopathy.  
- Contraindications for transfemoral access: 
1. Excessive tortuosity of the ilio-femoral axis.  
2. Previous aorto-bifemoral by-pass surgery. 
3. Small iliac or femoral artery diameter (<6-8mm depending on the device). 
4. Severe angulation of proximal ascending aorta or the valvular plane. 
5. Severe atheromatosis of ascending aorta or aortic arch, aortic coarctation, aneurism or 
dissection of descending thoracic aorta or abdominal aorta, specially if wall thrombus is 
present. 
*In case of TAVI indication and contraindication of femoral access, subclavian access 
might be considered. 
**In case of femoral/subclavian access contraindication, transapical access might be 
considered. 
- Contraindications for transapical access: 
1. Previous cardiac surgery on left ventricle apex. 
2. Paricardium calcifications. 
3. Chronic respiratory insufficiency that contraindicates minithoracotomy. 
4. Apical thrombus in left ventricle. 
3.2 TAVI program development 
Before starting a new transcatheter program is essential to proceed with the organization of 
a local heart team that must be formed by two cardiothoracic surgeons, two interventional 
cardiologists, an echocardiographist, an anesthesiologist, two dedicated nurses, and a 
perfusionist. Problem-solving skills and learning ability are essential, as it is the 
collaboration among the different departments and units involved in order to front the 
complications that will arise during the learning curve. 
Because of the elevated costs of the device, the difficulty of the technique and the high-risk 
profile of the candidates, specific learning courses realization is mandatory, as well as 
continuing training all along the team assistance trajectory. Industry demands, for both 
CoreValve and Sapien devices, a 15 procedures period in which the presence of a proctor 
that leads and trains the heart team is recommended before the achieving of the 
accreditation as an independent unit.  
Patient screening must be performed with exquisite care as the success or failure of the 
starting program could depend on the results of the initial cases. We must never forget that 
elective therapy for severe aortic stenosis is still surgical replacement, and only when 
surgery is contraindicated or very risky TAVI can be considered. TAVI indication must be 
established after consensus between the heart team dedicated to this technique and the 
clinical cardiologist responsible of the candidate and not only clinical but economic criteria 
must be taken into account as the elevated expenses that this procedures involve requires 
the proper selection that may lead to optimal clinical long term results, both in terms of 
survival expectancy and quality of live. 
Bullesfeld et al reported that pre-procedure patient functional class, assessed by Karnofsky 
index, was the only in-hospital survival predictor after CoreValve implantation. This fact 
comes to point again the main importance that an exhaustive screening process has in terms 
of late clinical results, and so in terms of efficiency (Bullesfeld L et al., 2009). 
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3.3 Additional diagnostic tests 
Usual imaging complementary tests performed before TAVI are transthoracic 
echocardiography, transesophageal echocardiography, cardiac catheterization and coronary 
angiography and CT-scan and/or C-MRI. In addition to confirmation of aortic stenosis 
severity, detailed basic information is required regarding (Delgado V et al., 2010): 
- Valve morphology (tricuspid or bicuspid, extend of calcification). 
- Annulus diameter. 
- Left ventricular outflow tract (LVOT) morphology. 
- Morphology of the aortic root (sinuses and their relation to extensive valve 
calcification) 
- Distance between coronary arteries and annulus (relation to sinus morphology and 
extensive valve calcification). 
- Size, pathology (complex plaques, aneurysm) and course (kinking) of the entire 
aorta. 
- Size, pathology (calcification) and course (tortuosity) of iliac and femoral arteries. 
The consolidation of transcatheter aortic valve implantation procedures in the common 
practice will be related to the results obtained. Imaging techniques improvements and its 
application during the procedure can help to obtain better results. 3D-Transesophageal 
echocardiography will contribute with valuable information about device positioning, valve 
function and relation between the prosthesis and the coronary ostia and the aortic root. It is 
especially valuable in the assessment of leaflets calcifications that might cause early in-
procedure complications during the valve deployment and will help the operator to find the 
proper positioning at the same time that allows identifying perivalvular leaks and guiding 
corrective manoeuvres in order to gain final prosthetic normal function and optimal 
performance. (Ng AC et al., 2010)  
DynaCT is being introduced in the most advanced hybrid catheterization laboratories, 
adding a new tool that offers incomparable information about aortic root configuration and 
relations among the different structures involved in TAVI procedures, but at this moment, it 
is only available in a very few centres and, however in the next future it may become the 
usual guiding diagnostic tool, it cannot be considered as a standard requirement at this 
moment.  (Kempfert J et al,. 2009) 
3.4 Operating room 
The ideal place to perform these complex techniques is called hybrid operating room or 
hybrid catheterization laboratory, were both, optimal x-ray imaging facilities and surgical 
treatment of the room adequate for cardiopulmonary by-pass, join together in order to 
minimize the risk of complications and adopt the necessary therapeutic measures in case of 
their presentation. The elevated cost of these hybrid rooms and the considerably big space 
that require make them to be out of reach for many centers, so several portable x-ray devices 
are being approved for its use into standard operating rooms. 
3.5 Complications 
Most often complication that may present in the early post-procedure period are: valve 
malposition, peri-prosthesis leak, acute aortic regurgitation and acute lung oedema, device 
embolization, low cardiac output heart failure with hemodynamic support requirements, 
conventional surgery conversion with in-pump connection, vascular access complications 
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including vessel rupture, dissection and/or acute occlusion, stroke, myocardial infarction, 
coronary ostia occlusion, atrioventricular block and renal failure.  
Valve malposition and valve embolization:  
Valve malposition and valve embolization are classical complications very related to the 
different teams learning curve and the technical improvements in the deployment devices. 
They have been drastically reduced from initial series (approximately 6%) to the incidence 
reported in the pate trials (approximately 2%). (Walther T et al,. 2007) 
Peri-prosthesis leak: 
Peri-prosthesis leak is due to absence of complete apposition of the device to the aortic 
annulus caused by lack of homogeneous expansion and it is one of the most common 
complications and the most important factor related to post-procedural aortic regurgitation. 
This valve regurgitation, when it is severe, can generate acute hemodynamic instability and 
acute lung oedema (that also may appear after pre-implantation balloon valvuloplasty) and 
it is one of the most important issues to improve in order to achieve a real advance in this 
technique (Cribier A et al., 2006).  
Vascular access complications:  
Vascular access major complications are still over 10% in the majority of the series reported 
despite the results improvements. Experience with the CoreValve system indicates that 
transporter catheter diameter reduction has great impact in the reduction of these 
complications (from over 20% to 5% in the last registries). In addition to this, 22F catheter 
maintenance for Edwards Sapient system lead to a stabilization in the incidence of vascular 
complication despite the operators experience gaining. Anyway, it seems that, at least in the 
SOURCE registry, vascular complications do not determine higher 30-days mortality 
incidence. This suggests that the presence of highly prepared teams with experience in the 
treatment of these vascular complications may limit their impact in peri-procedural 
mortality.  
It is important to advice that not only transfemoral technique is related to access 
complications as transapical access has also been associated with serious access 
complications as ventricular tear or severe bleeding during apex reparation. (Dumont E et 
al,. 2009, Rodés-Cabau J et al,. 2010) 
Stroke: 
Stroke, because of its terrible consequences for the patient, it has been another major concern 
of this technique. Stroke incidence has been kept below 5% in the majority of series; that is 
quite inferior to the expected incidence in an octogenarian population who undergo 
standard cardiac surgery with aortic clamping. This supports the idea that conventional 
aortic replacement surgery with cardiopulmonary by-pass and aortic clamping has a higher 
risk of stroke than these newer techniques despite the necessity of big sized aggressive 
devices that must navigate the aortic arch during implantation. It is important to remark 
here that transapical access avoids the manipulation of these catheters in the aorta and last 
trials have reported a tendency towards a stroke incidence reduction, so many centres have 
given priority to this access when severe aortic atheromatosis or porcelain aorta are present 
(Grube E et al,. 2008; Rodés-Cabau J et al,. 2010). 
Myocardial infarction: 
Assessing the incidence of myocardial infarction as a complication of TAVI is a very difficult 
objective as myocardial infarction definitions are quite variable among different trials and 
registries. Incidence vary from 0,2 to 17,5% depending on the definition given. In terms of 
severity and device-related myocardial infarction, the most important pathophysiological 
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condition that must be watched is the occlusion of a coronary ostium secondary to calcified 
native valve leaflets displacement, much more frequent than ostium jailing phenomenon 
caused by the stent struts. Several groups have remark the importance of adequate 
assessment of the distance between the aortic annulus and coronary ostia to avoid this 
dramatic complication, especially in cases with severe calcifies native valve. Predicting peri-
procedural myocardial infarction secondary to previous coronary disease would be much 
more difficult. Actually approved devices producers recommend the prophylaxis of this 
complication by coronary angiography and eventually percutaneous coronary intervention 
that should be performed at least 48 hours before TAVI. (Kapadia Sr et al,. 2009; Bagur R,. 
2010; Wood D et al,. 2009) 
Atriventricular block: 
Atrioventricular block and need for pacemaker implantation has shown to be related to a 
low positioning of the valve that leads to His bundle conduction system injury. Incidence 
of permanent pacemaker implantation requirements after trancatheter valve 
implantation may vary among registries, but it looks clear that is much more frequent 
after CoreValve implantation in comparison with the Sapien system (10-33% vs <7%. 
(Piazza N et al,. 2008; Grube E et al., 2008). This difference is explained by the design 
characteristics of the CoreValve: the bigger length of the prosthesis favours under-aortic 
annulus anchorage and the nitinol autoexpandable alloy determines an additive 
progressive expansion of the stent after the deployment, with the subsequent risk of 
electric conduction system injury. 
With such a high-risk of AV block, emphasis in the search for predictors that can anticipate the 
need for permanent pacemaker has been done. Jilahihawi et al recently reported the presence 
of previous left-bundle atrioventricular block, a ventricular septum bigger than 17mm or a 
non-coronary leaflet bigger than 8mm as a predictor for pacemaker requirement with a 75% 
sensibility and 100% specificity. (Jilahihawi H et al., 2009) Nevertheless, more studies with 
bigger sample sizes are needed before making definitive recommendations about prophylactic 
measures focused on avoiding this important, although rarely lethal, complication.  
Advances in the knowledge of the aetiology and pathophysiologic generation of the 
atrioventricular block with different transcatheter valves will help to optimize final results. 
Alternative septum membranous anchorage systems that facilitate implantation on the 
native annulus and reduction of the terminal outflow tract cross-section size should be the 
key for improving results.  
Renal failure and haemodialysis requirements:  
Aregger et al evaluated the incidence of renal failure in a 54 patients cohort of CoreValve or 
Sapien implantation (Aregger F et al., 2009). The majority of the patients achieved an 
improvement in the creatinine serum levels after the procedure, but renal failure reached a 
28% and 7,4% required haemodialysis during hospitalization. Bagur et al have recently 
reported a renal failure incidence of 11,7% after the Edwards Sapien device implantation, 
with a 4-fold in-hospital mortality increase (Bagur R et al., 2010). Curiously, in the same 
paper, incidence of acute renal failure among patients with previous chronic renal failure 
was lower in the group of TAVI than in the group of standard surgical valve replacement 
(9,2 vs 25,9%; haemodialysis requirements: 2,5 vs 8,7%). 
3.6 Evidence 
Degenerative aortic stenosis is a pathological process with stable prognosis and well known 
history for years, it can be considered as a “classical” heart disease and it has experimented 
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very few advances during the past decades. Surgical valve replacement has shown itself as 
an excellent therapy and no alternative has arisen until the development of transcatheter 
valve implantation, and it has started its journey as a marginal palliative alternative for non-
operable patients, so virtually no field for multicentre randomized double-blinded clinical 
trial that provide statistically reliable information that can guide evidence-based 
recommendations. Hence, the beginnings of transcatheter aortic valve implantation could be 
described at least as “complicated” and many difficulties have been overcome before 
achieving the minimal necessary strength before reaching the clinical trials era that now we 
are observing. 
After initial heroic implantations performed by Cribier, Grub, Bonhoeffer or Webb, first 
experience was evaluated in several observational multicentre studies like SOURCE, 
REVIVE, REVIVE II and REVIVAL (Kodali SK et al., 2011). This studies reported valuable 
information about feasibility and safety of the technique with promising clinical results, but 
clinical randomized trials are needed before extracting definite conclusions about the true 
clinical benefits of transcatheter aortic valve implantation.  
The SOURCE trial was a post-commercialization study in with the participation of 34 
european centres that included a total of 463 patients with severe symptomatic aortic 
stenosis who underwent transfemoral aortic valve implantation because of severe 
comorbidities that made standard surgical therapy contraindicated or too risky. Immediate 
success of the procedure was achieved in 95,6% and 30-days after procedure survival was 
93,7% in the whole cohort and 88,6% among patients who suffered vascular access 
complications. Other common complications reported were: pacemaker implantation (6,7%), 
aortic regurgitation > grade 2 (3,2%), device malaposition (1,7%) and coronary occlusion 
(0,7%). There was no device embolization event.(Wendler O et al., 2010; Thomas M et al., 
2010)  
After the initial results achieved during the first era and the spreading of the technique, 
major adverse cardiovascular events, in-hospital admittances, post-procedural functional 
class, complications, costs and quality of live are issues that must be contrasted no only 
against medical conservative therapy but also against conventional surgical treatment in this 
subset of high risk patients (but still considered operable). If clinical results still remain 
positive, long term follow-up and durability might be considered in order to extend clinical 
indication to lower risk profile patients. 
After these first promising results it seems to be reasonable to affirm that TAVI is a 
feasible alternative to standard surgery for very high-risk patients, that allows offering 
them better expectative of survival and quality of life than a conservative pharmacological 
strategy. 
In general, multicenter registries have included more than 2000 patients with an overall 
success over 90% and a 30-days mortality <10%, a definite step in order to confirm the 
feasibility, safety and efficacy of this technique as an alternative to surgical standard 
replacement in the subgroup of high-risk or prohibitive risk patients. At this point, direct 
comparison with surgical replacement does not look like a non-reachable objective, at least 
for the subgroup of patients in the frontier of the cardiopulmonary by-pass surgery 
indication (risk high enough to consider alternatives but not so much to be firmly rejected). 
This issue is the aim of the next generation of clinical trials involving TAVI. 
In this way, the PARTNER trial pretends to give the response to these questions that initial 
practice arose. During the first part of this trial, patients with a diagnose of severe 
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symptomatic aortic stenosis and rejected for surgery were randomly assigned into two 
groups: standard pharmacological conservative therapy or transcatheter aortic valve 
implantation. The results of this first step were reported in October 2010 and they showed a 
one-year mortality of 30,7% in the TAVI group vs 50,7% in the conservative therapy arm. 
Differences in hospital admission needs were as well statistically significant (42,5% in the 
TAVI group vs 71,6% in the conservative group) and a benefit in terms of functional class 
was observed too (NYHA class III/IV of 25,2% in TAVI group vs 58% in the 
pharmacological group), however, the incidence of stroke showed to be higher in the TAVI 
group (5% vs 1,1%) so they did vascular complications. (León MB et al., 2010) 
Second part of PARTNER trial is actually on course and will try to compare the results of 
severe symptomatic aortic stenosis patients with very-high risk surgical profile randomly 
assigned into a group of standard surgical valve replacement or TAVI. Clinical events are 
being collected and publications of the results are expected for this year. They probably will 
guide the final clinical recommendations in the management of this complicated subgroup 
of patients. 
Many individual and multicentre trials are on course at this moment trying to evaluate the 
efficiency of TAVI. As it is a novel technique in continuous evolution, European societies 
have recently published the guidelines to define the main endpoints that must be recorded 
in order to perform a conceptual standardization, that may serve as a reference for future 
comparisons among different studies and avoid possible biases.  
A medicine based clinical practice and the rational application of these novel techniques 
(doing the essential exhaustive screening in order to select the best candidates to gain 
clinical benefit) will balance the performing of these promising procedures with more or less 
demonstrated results and the enormous commercial pressure that these devices 
development and researching suffer. We cannot forget the international economic situation 
that we are witnessing at this moment and we must show ourselves with clinical common 
sense enough to ensure maximum efficiency. If this is not guaranteed, exaggerated expenses 
and bad clinical results might lead to fail in the introduction of promising innovations 
before they are really tested. 
As transcatheter aortic valve implantation techniques are spreading, newer indications for 
their use are extending with excellent initial results. That is the case of biological aortic 
prosthesis degeneration after conventional cardiac surgery. The anchoring of the 
transcatheter valve over the degenerated prosthesis seems to be quite safe and facilitate the 
treatment of patients that cannot undergo a surgical reintervention. We must wait until 
large series results to be reported before extract conclusions, but this is an obvious new field 
for the application of TAVI that can give response to an emerging problem as the population 
of developed countries keeps on aging.  
3.7 Mid and long term follow-up results 
There are relatively few data about mid and long-term follow-up results after transcatheter 
aortic valve implantation. The one-year survival after transfemoral implantation has 
reached 80% ore over in the most recent registries like SOURCE. It is interesting to remark 
the late publication in this sense of Webb et al where the majority of deaths that appear after 
30 days are demonstrated to be non-cardiac related. This fact underlines again the main 
importance of making a proper patient selection in order to achieve good long-term results. 
Canadian multicentre experience (Rodés-Cadau J et al., 2010), that included transfemoral 
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and transapical access, demonstrated that the presence of extra-cardiac comorbidities as 
renal failure or chronic obstructive pulmonary disease were two of the most importantly 
late mortality related factors. Finally, with the available data until date, no structural 
damage has been found yet in the mid-term follow up. 
Recent long-term results of a single centre have been reported with the transfemoral 
CoreValve system in 450 patients. Pre-procedure logistic EuroSCORE was over 20% in >90% 
of the cohort. Early in-hospital mortality has been decreasing during last two years until 
stabilization in 6%. Other in-hospital complications have decreased as well with the 
exemption of pacemaker requirements that stabilizes in 39%. Stroke appeared in 1,6% of the 
patients. One-year survival was 60% with the 25F device, 79% with the 21F and 84% with 
the 18F, remarking the critical importance that the design improvement holds.  
Transapical procedures have been related to one-year survival rates <80%, even in recent 
registries as SOURCE, probably due to higher risk basal characteristics of patients selected 
for this approach. Lichtenstein et al reported their initial experience in seven severe aortic 
stenosis patients that presented bad vascular access and severe comorbidities (Lichtenstein 
et al., 2006). Valve was implanted through a minimal thoracic incision and apex puncture 
without cardiopulmonary by-pass. There was no early mortality or valve dysfunction in this 
report. One year later, Walther et al reported their initial experience in a 30 patients cohort. 
Valve implantation was successfully implanted in 29 and one patient required cardiac 
surgery conversion with median sternotomy. After these reports, the possibility for an 
alternative access route when lack of vascular access is present was demonstrated. The same 
late author reported the experience of 4 centres that treated 59 patients with a mean 
EuroSCORE of 24±14% intended for Edwards–Sapien transcatheter heart valve 
implantation. Procedure was performed successfully in 53 patients when 4 patients required 
sternotomy and standard surgery conversion. Early in-hospital mortality was 13,6% and no 
prosthesis dysfunction was observed. (Walther T et al 2007) 
Out of Europe, four American centres also reported their initial experience with the first 40 
Edwards-Sapien implantation tries. The valve was successfully implanted in 35 patients. 30-
days mortality was 17,5% and in a 143 days follow-up 6 more patients died, so Kaplan-
Meier curves showed survival rates of 81,8±6,2% at one month, and 71,7±7,7% at 3 months. 
The PARTNER EU registry included 69 severe aortic stenosis patients with serious 
comorbidities, high-risk surgical profile (mean logistic EuroSCORE 33,8±14,7%) and poor 
vascular access. Technical device implantation success was achieved in 91%. 30-days 
mortality was 18,8%; stroke 2,9%, conversion to standard surgery 2,9% and permanent 
pacemaker 4,4%. On-year survival was 50% and an important improvement in functional 
class was recognized for the majority of patients. 
The largest cohort of transapical Edwards-Sapien implantation is the one in the SOURCE 
registry, with 575 patients. Mean logistic EuroSCORE was 29,2% and primary procedure 
success was reached in 92,8%. Conversion to standard surgery was reported in 3,5%, severe 
aortic regurgitation in 5,9an valve malaposition in 1,4%. 30-days mortality was 10,3%, stroke 
2,9% and permanent pacemaker implantation 7,3%. 
Medical industry has found in TAVI an open door for alternative treatment demands, so 
many companies are promoting research and developing of newer devices at this moment. 
Sadra Lotus, Direct Flow, Sorin Perceval, 3F Endurance Valve, LPI Repositionable, Lutter 
Valve, Heart Leaflet Technologies, Aortech and Artx valves may serve as an example. 
Summarizing, we are now witnessing the beginning of a new era in the development of 
therapies for patients affected of aortic stenosis. The rigorous selection of patients and the 
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rigorous obtaining of clinical data from trials and registries will determine the permanence 
and rising of this highly promising short of therapies. 
4. Sutureless biological aortic valve surgical replacement 
Clinical short and long term results of conventional aortic valve replacement have been 
clearly established along the last decades. At this moment, medical industry is developing a 
new short of biological aortic valve prosthesis that, despite the standard cardiopulmonary 
by-pass and aortic clamping need, they hold the advantage of a sutureless implantation 
system that leads to a faster surgery with less on-pump time with the evident benefits in 
terms of surgical risks. Interesting alternative application of sutureless valves is the redo 
surgery (re-interventions after prosthesis dysfunction). In this short of surgery, as it is 
always complex and risky, reducing aortic clamping time is essential, so these sutereless 
valves may offer an inestimable help by accelerating the valve insertion process. In case of 
biological dysfunctional prosthesis, sutereless valves allow a valve-in-valve implantation 
without the extraction of the previous dysfunctional valve. This procedure is performed by 
deployment of the sutureless valve within the pre-implanted valve stent-annulus, avoiding 
this way the risks involved in prosthesis removal (aortic root and annulus manipulation and 
prolonging clamping time). 
This kind of prosthesis generate very low hemodynamic gradient because they are 
constructed over a low profile metallic stent, with a similar structure to transcatheter-
deployable devices. This advantage improves valve hemodynamics and may contribute to 
ventricular mass regression.  
The commercial bid of this group of prosthesis is based on its capacity to reduce the 
aggression of standard surgery, favouring the realization of progressively less invasive 
surgical techniques (ministernotomy, minithoracotomy, robotic surgery…) and the adding 
value of its contribution on the researching and development of future transcatheter 
devices. 
Sorin´s Perceval and 3F´s Enable are the more promising models at this moment. The 
companies involved in the production of this prosthesis are those who may point the aim of 
this technique: development of newer transcatheter devices or really improve standard 
surgery results.(Shrestha M et al., 2009, Aymard T et al., 2010) 
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Enable 3F Valve 
5. Apicoaortic conduits 
Surgical aortic valve replacement by median thoracotomy under cardiopulmonary bypass is, 
as mentioned above, the standard therapy for severe aortic stenosis that has proven 
superiority to conservative pharmacological therapy. Many times, however, this treatment 
cannot be performed because of different technical, anatomic or clinical problems that the 
patient may present, as it could be porcelain aorta or tiny aortic annulus. Aortic valve conduits, 
also known as apicoaortic conduits, are a short of devices designed in the sixties to give an 
alternative in these situations. Apicoaortic conduits connect the left ventricle apex with the 
descending thoracic aorta, relieving the intraventricular pressure by allowing the blood flow to 
find a way out of the heart without fighting against the aortic valve resistance. Because the 
operation was technically difficult, it had fallen into disuse, but, with the introduction of 
technically easier and less invasive procedures performed by minithoracotomy, this alternative 
offers clear advantages over standard valve replacement (avoidance of sternotomy, 
cardiopulmonary bypass, cardioplegic cardiac arrest, native valve debridement, conduction 
system injury, aortic cannulation, and aortic cross-clamping) and arises as another option in 
addition to transcatheter aortic valve implantation as alternative therapy for high risk patients. 
This technique offers the possibility to choose from a big variety of valve models and sizes, it  
 
 
Aorto-apical conduit Medtronic Hancock 
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has proven long-term efficacy and durability, involves lower peri-procedural stroke risk and 
has no incremented AV block or paravalvular leak risks. As disadvantage, it commonly 
requires cardiopulmonary bypass pump, though some off-pump cases have been reported 
(Vassiliades TA Jr et al 2003; Hirota M et al;  Chahine JH et al., 2009)  
6. Conclusions 
As the developed countries population continues its progressive aging, number of patients 
grows as the majority of cases, with the subsequent increase in co-morbidities and risk profile 
worsening. In the other hand, technical improvements and innovation in newer devices design 
and performance make these alternatives more and more attractive. In this scenario, the data 
reported by big clinical trials as PARTNER may result in a deep revolution in degenerative 
aortic stenosis management, where minimal invasive procedures arise as the procedures of 
choice for this high-risk population. We must wait until definitive publications in this way 
before introducing any change in the clinical practice guidelines, but at this moment we can be 
quite confident about the fact these novel techniques “are here to stay” 
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